Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3808904 | 1.00 | LMNA (0.43) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL3022156 | 0.81 | ADORA2A (0.55) | ADORA3ADORA1ADORA2AHTR2B | |
| SCHEMBL2806725 | 0.81 | ADORA3 (0.49) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL3040267 | 0.77 | PDE4D (0.55) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL30827047 | 0.77 | PDE4D (0.55) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL4360551 | 0.76 | LMNA (0.42) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL242794 | 0.75 | LMNA (0.49) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL8918687 | 0.75 | LMNA (0.49) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL1412086 | 0.74 | LMNA (0.38) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL8960152 | 0.73 | LMNA (0.43) | LMNATP53ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044070-B1 | PURINE DERIVATIVES AS A2A AGONISTS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-8188100-B2 | Adenosine derivatives as A2A receptor agonists | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2066669-B1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | NOVARTIS AG (CH) | 2010-08-05 | — | — | US | disclosed |
| EP-2205601-A1 | PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| WO-2009050199-A1 | PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| EP-2044070-A1 | PURINE DERIVATIVES AS A2A AGONISTS | Novartis AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| EP-1903044-A1 | Adenosine Derivatives as A2A Receptor Agonists | Novartis AG (CH) | 2008-03-26 | — | — | EP | disclosed |
| EP-1889846-A1 | Purine derivatives as A2a agonists | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008006563-A1 | PURINE DERIVATIVES AS A2A AGONISTS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | ADORA2A, ADORA1, ADORA3 | LMNA 2449/4885TP53 4185/4885ALDH1A1 596/4885 |
| US-20100240680-A1 | Purine derivatives as a2a agonists | ADORA2A, ADORA1, ADORA3 | LMNA 2590/4885TP53 3965/4885ALDH1A1 702/4885 |
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | ADORA2A, ADORA2B, ADORA1 | LMNA 2569/4885TP53 3227/4885ALDH1A1 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.